| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| BIOS | BioScrip, Inc. | $2.99 | $382.86M | Downtrend |
INmune Bio prices IPO at $8
https://seekingalpha.com/news/3423240-inmune-bio-prices-ipo-8?source=feed_news_all
Jan 15, 2019 - INmune Bio (INMB) prices its "best efforts" IPO at $8 per share, expecting to raise $8M - 20M depending on demand (1M - 2.5M shares).The company develops immunotherapies that it says harness t
0
Array Bio up 11% premarket on positive late-stage data on triplet therapy for certain type of colorectal cancer
https://seekingalpha.com/news/3423001-array-bio-11-percent-premarket-positive-late-stage-data-triplet-therapy-certain-type?source=feed_news_all
Jan 15, 2019 - Array BioPharma (NASDAQ:ARRY) is up 11% premarket on light volume on the heels of its announcement of updated data from a Phase 3 clinical trial, BEACON CRC, evaluating the combination of BRAFTOVI (en
0
Assembly Bio advancing studies of HBV candidate ABI-H0731; investors unmoved, shares down 17% this week
https://seekingalpha.com/news/3422141-assembly-bio-advancing-studies-hbv-candidate-abi-h0731-investors-unmoved-shares-17-percent?source=feed_news_all
Jan 10, 2019 - Thinly traded micro cap Assembly Biosciences (ASMB -10%) is down on double normal volume. Shares have retreated 22% since touching the intraday high of $25.68 on Monday and are down 17% for the week.I
0
Hemispherx Bio up 22% on Ampligen + Keytruda studies
https://seekingalpha.com/news/3421524-hemispherx-bio-22-percent-ampligen-keytruda-studies?source=feed_news_all
Jan 08, 2019 - Thinly traded nano cap Hemispherx Biopharma (HEB +22.1%) is up on a 7x surge in volume in reaction to its announcement of two clinical trials evaluating the combination of Ampligen (rintatolimod) and
0
ADMA Bio up 7% on submission of responses to Bivigam CRL
https://seekingalpha.com/news/3421023-adma-bio-7-percent-submission-responses-bivigam-crl?source=feed_news_all
Jan 07, 2019 - ADMA Biologics (ADMA +7.1%) is up on below-average volume in following its announcement that it has submitted its responses to the CRL it received from the FDA in December 2018 in response to its mark
0
Alder Bio inks $100M stock sales deal with JPMorgan
https://seekingalpha.com/news/3420848-alder-bio-inks-100m-stock-sales-deal-jpmorgan?source=feed_news_all
Jan 04, 2019 - Alder BioPharmaceuticals (NASDAQ:ALDR) enters into a $100M at-the-market stock sales agreement with JPMorgan who will earn a 3% commission for its efforts.
0
Arcus Bio down 14% on COO departure
https://seekingalpha.com/news/3420790-arcus-bio-14-percent-coo-departure?source=feed_news_all
Jan 04, 2019 - Thinly traded micro cap Arcus Biosciences (RCUS -13.9%) is down on almost double normal, albeit on turnover of only 439K shares, in response to the announced exit of COO and CFO Jennifer Jarrett to &#
0
Atara Bio up 9% after yesterday's CEO departure-stoked selloff
https://seekingalpha.com/news/3420717-atara-bio-9-percent-yesterdays-ceo-departure-stoked-selloff?source=feed_news_all
Jan 04, 2019 - Atara Biotherapeutics (ATRA +8.5%) is up on average volume in early trade as buying recovers after yesterday's 19% plummet in reaction to the planned departure of CEO Isaac Ciechanover, M.D.Cheerleade
0
14 Steps To Writing Great Financial Advisor Bios
https://seekingalpha.com/article/4231415-14-steps-writing-great-financial-advisor-bios?source=feed_all_articles
Jan 04, 2019 - Your bio is your opening shot at overcoming readers’ ingrained apprehension about financial salespeople. Spend extra time on the opening.Tell your story. This is your first and best chance to humanize
0
Atara Bio in-licenses CAR-T candidate from Memorial Sloan Kettering
https://seekingalpha.com/news/3420456-atara-bio-licenses-car-t-candidate-memorial-sloan-kettering?source=feed_news_all
Jan 03, 2019 - Atara Biotherapeutics (ATRA -9%) has exclusively in-licensed a mesothelin-targeted CAR-T therapy from Memorial Sloan Kettering Cancer Center.Mesothelin is a protein that is highly expressed in certain
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| CIVI | Civitas Solutions, Inc. | NYSE | $14.35 | $519.89M |
| CCM | Concord Medical Services Holdings Limited | NYSE | $3.499 | $151.73M |
| PETS | PetMed Express, Inc. | NASDAQ | $36.88 | $762.88M |
| ADUS | Addus HomeCare Corporation | NASDAQ | $68.95 | $806.53M |
| KANG | iKang Healthcare Group, Inc. | NASDAQ | $17.41 | $1.21B |
BIOS - Nasdaq
http://www.nasdaq.com/symbol/bios
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
BIOS - Google Finance
https://www.google.com/finance?q=BIOS
Industry related info and international coverage
Summary
News
BIOS - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIOS
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options